Abstract
With the aim of becoming the leading player in the fragmented dermatology market within 5 years, Valeant Pharmaceuticals has continued its deal making in this area by agreeing to acquire the assets of the Ortho Dermatologics division of Johnson & Johnson’s Janssen Pharmaceuticals for US$345 M. The division reported revenues of approximately US$150 M in 2010 from sales of prescription drugs such as Retin-A-Micro® (tretinoin gel), Ertaczo® (sertaconazole nitrate) and Renova® (tretinoin cream).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
